Lv2
115 积分 2022-06-06 加入
Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI‐Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2‐Low Status of Breast Cancer
5天前
已完结
Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives
12天前
已完结
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
14天前
已完结
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer
17天前
已完结
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
24天前
已完结
Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial
24天前
已完结
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial
28天前
已完结
Neoadjuvant therapy for pancreatic cancer
1个月前
已完结
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)
1个月前
已完结
Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors
1个月前
已完结
皖公网安备34019202002308
